会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 14. 发明公开
    • 조골 세포와 생체 기질 성분의 혼합물을 이용한 골 생성용조성물 및 그 제조방법
    • 骨质疏松和生物基质混合物的骨形成组合物及其制造方法
    • KR1020060129792A
    • 2006-12-18
    • KR1020050050447
    • 2005-06-13
    • 세원셀론텍(주)
    • 장재덕박현신장정호정수진이새봄고창권
    • A61K35/32A61K38/39A61K38/48A61K38/36
    • A61K35/32A61K35/12A61K38/4833A61L27/3821A61L27/3847A61L27/3895A61L2430/02C12N5/0654C12N2533/56A61K38/363A61K38/39
    • A bone formation composition comprising a mixture of osteoblast and bio-matrix and its manufacturing method are provided to avoid clinical rejection of its administration by administering the composition into a desired region of a subject, prevent bone formation at the undesired region induced by transferring the osteoblast into the undesired region through the blood by administering the osteoblast suspension, and reduce the time of bone formation. The method for manufacturing the bone formation composition comprises the steps of: separating osteoblasts from the tissue, culturing the osteoblasts in DMEM(Dulbecco's modified Eagle's medium) or alpha-MEM(minimum essential medium, alpha modification) to prepare the osteoblast suspension; and adding the bio-matrix into the osteoblast suspension, wherein the method further comprises a step of adding a coagulant such as thrombin and fibrinogen; and the bio-matrix is collagen or hydroxyapatite. The bone formation composition comprises the mixture of osteoblast and bio-matrix as active ingredients.
    • 提供包含成骨细胞和生物基质的混合物的骨形成组合物及其制备方法,以通过将组合物施用于受试者的期望区域来避免其施用的临床排斥,从而防止在通过转移成骨细胞诱导的不希望的区域的骨形成 通过施用成骨细胞悬浮液通过血液进入不需要的区域,并减少骨形成的时间。 用于制备骨形成组合物的方法包括以下步骤:从组织中分离成骨细胞,在DMEM(Dulbecco's modified Eagle's培养基)或α-MEM(最小必需培养基,α修饰)中培养成骨细胞以制备成骨细胞悬液; 并将所述生物基质添加到所述成骨细胞悬液中,其中所述方法还包括加入凝血剂如凝血酶和纤维蛋白原的步骤; 生物基质是胶原蛋白或羟基磷灰石。 骨形成组合物包含成骨细胞和生物基质作为活性成分的混合物。
    • 15. 发明公开
    • 분화된 어린 지방 세포와 생분해성 중합체의 이식에 의한신체의 부피 대체 방법
    • 差异分布不明的移植物和生物可降解的组织用于组织补充
    • KR1020060110637A
    • 2006-10-25
    • KR1020050033091
    • 2005-04-21
    • (주)안트로젠
    • 이성구김미형김인옥
    • C12N5/077A61K35/35
    • A61L27/3804A61K35/12A61L27/3895C12N5/0653C12N2533/56C12N2533/74A61K35/35
    • A method of transplanting differentiated immature adipocytes with biodegradable scaffold for tissue augmentation is provided to treat the loss of soft tissue and appearance lesions without their destruction and reduction of engraftment rate. A composition for tissue augmentation comprises immature adipocytes differentiated from preadipocytes derived from fat tissue and having the diameter of 20-40mum, wherein the composition is used for autologous or heterologous transplantation in mammals. The transplantation method of immature adipocytes differentiated from preadipocytes and biodegradable scaffold for tissue augmentation comprises the steps of: (a) differentiating preadipocytes isolated from autologous or heterologous fat tissue into adipocytes; (b) collecting the differentiated immature adipocytes having the diameter of 20-40mum; (c) in vitro coculturing the collected differentiated immature adipocytes and biodegradable scaffold; and (d) transplanting the cultured immature adipocytes and biodegradable scaffold into the mammal body by injection or surgical operation.
    • 提供用生物降解支架移植分化的未成熟脂肪细胞用于组织增大的方法,以治疗软组织和外观损伤的损失,而不破坏和降低植入率。 用于组织增强的组合物包含与源自脂肪组织的前脂肪细胞分化的直径为20-40μm的未成熟脂肪细胞,其中所述组合物用于哺乳动物中的自体或异源移植。 从前脂肪细胞分化的未成熟脂肪细胞的移植方法和用于组织增生的可生物降解支架包括以下步骤:(a)将从自体或异源脂肪组织分离的前脂肪细胞分化成脂肪细胞; (b)收集直径为20-40μm的分化不成熟的脂肪细胞; (c)体外共培养收集的差异未成熟脂肪细胞和可生物降解的支架; 和(d)通过注射或外科手术将培养的未成熟脂肪细胞和可生物降解的支架移植到哺乳动物体内。